Cadila Healthcare Reported Receiving DCGI Approval For Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Cadila Healthcare reportedly has received India approval for its diabetes dyslipidemia drug, saroglitizar, named after a word in the language of the Indian state of Gujarat, considered one of the nation's capitals for the disease.